The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

New Hepatitis C Treatment Approved By the FDA

Back to News Homepage

Next

FDA Grants Priority Review: Once-Daily, Single-Tablet Combination for HCV

Safe and Effective Drug for Hepatitis C Genotype 4

July 27, 2015

Print this page

Learn more about Technivie, a new Hepatitis C treatment approved by the FDA.

FDA approves Technivie for treatment of chronic hepatitis C genotype 4

The U.S. Food and Drug Administration today approved Technivie (ombitasvir, paritaprevir and ritonavir) for use in combination with ribavirin for the treatment of hepatitis C virus (HCV) genotype 4 infections in patients without scarring and poor liver function (cirrhosis).

Technivie in combination with ribavirin is the first drug that has demonstrated safety and efficacy to treat genotype 4 HCV infections without the need for co-administration of interferon, an FDA-approved drug also used to treat HCV infection.

Continue reading this FDA News Release:
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm455857.htm

No Comments - be the first!
Share
Share

Previous

New Hepatitis C Treatment Approved By the FDA

Back to News Homepage

Next

FDA Grants Priority Review: Once-Daily, Single-Tablet Combination for HCV

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.